Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.23 CAD
Change Today +0.015 / 6.98%
Volume 40.0K
APC On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 2:49 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

advanced proteome therapeuti (APC) Snapshot

Open
C$0.24
Previous Close
C$0.22
Day High
C$0.24
Day Low
C$0.23
52 Week High
09/12/14 - C$0.32
52 Week Low
03/18/15 - C$0.09
Market Cap
25.0M
Average Volume 10 Days
27.6K
EPS TTM
--
Shares Outstanding
108.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADVANCED PROTEOME THERAPEUTI (APC)

Related News

No related news articles were found.

advanced proteome therapeuti (APC) Related Businessweek News

No Related Businessweek News Found

advanced proteome therapeuti (APC) Details

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company. It focuses on the development of a patent-pending technology that combines multiple anti-cancer therapies in a single agent to directly target cancer tumors. The company is headquartered in Boston, Massachusetts.

advanced proteome therapeuti (APC) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $175.0K
Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

advanced proteome therapeuti (APC) Key Developments

Advanced Proteome Therapeutics Announces Promising Results of Triple Combination Immunotherapy Tests

Advanced Proteome Therapeutics Corporation announced the first results of testing a triple combination of immunotherapies in animal models. These preliminary tests were carried out in conjunction with its academic collaborators. The tests compared the effects of the triple combination on tumor retardation and tumor free survival in an animal study with those of an anti-CTLA-4 antibody, a 41-BB antibody, or APC 104, separately, as well as in the various double combinations. The triple combination proved to be superior in retarding growth of tumors from implanted CMS5 tumor cells as well as increasing tumor free survival. Tumor free survival (TFS) was recorded in eight cohorts of mice over several weeks. Tumor free survival was 80% in mice treated with the triple combination (group 8) at the endpoint of the study. By contrast, during the same period, TFS varied in the other groups involving the administration of single entities and double combinations from 0% (group 2), 20% (group 3), 40% (groups 4, 5) to 60% (groups 6, 7). Untreated mice (group 1) did not survive beyond 3 weeks. These tests feature APC 104 in combination with both a checkpoint inhibitor (an anti-CTLA-4 antibody) and the co-stimulatory molecule 41-BB. The latter is known to increase the proliferation of immune cells capable of killing tumor cells and to enhance tumor rejection. APC 104 is a molecule which has been designed to increase the duration of action of APC’s protein delivery system to tumors. The recent clinical success of immunotherapies that interfere with immune checkpoint receptors has resulted in a surge of interest in immunotherapy as a mainstream form of cancer treatment. However, checkpoint inhibition alone, which releases the brakes on the immune system, although strikingly effective in specific subsets of patients, is not sufficient to promote tumor regression in a majority of patients.

Advanced Proteome Therapeutics Corporation Appoints Dr. David Webb to its Corporate Advisory Board

Advanced Proteome Therapeutics Corporation (APC or the company) announced that its Board of Directors has appointed Dr. David Webb to the Company's Corporate Advisory Board. Dr. Webb is currently Adjunct Professor at The Scripps Research Institute (TSRI). At Scripps he has focused on several areas relevant to drug discovery including the detection of circulating tumor cells.

Advanced Proteome Therapeutics Corporation Announces Positive Results in Combination Cancer Immunotherapy

Advanced Proteome Therapeutics Corporation (APC) reported results from its current round of experiments that not only reinforce previous evidence of the immunotherapeutic properties of APC's protein modification technology, but hold forth the possibility of synergistic effects with other immunotherapies while heralding the entry of a new and potentially powerful approach in the arsenal of anticancer weaponry. Over the past year, the company has demonstrated that APC's technology has the ability to overcome immune tolerance of certain tumors that have evolved mechanisms to evade attack by the body's immune system. APC has been able to enhance the affinity for target cancer cells of a natural human protein that possesses demonstrable anticancer activity, by modifying the protein chemically in a variety of ways. Indeed, various modifications of the protein, have translated into greater antitumor potency in animal models. Now, results from combination therapy with checkpoint inhibitors have demonstrated very promising results with the first molecule tested from APC's inventory of modified proteins. In experiments with animal models with tumor implants carried out with APC's academic collaborators, checkpoint inhibitors by themselves only slowed tumor growth, but did not cause tumor regression. By marked contrast, in parallel experiments using a combination of a checkpoint inhibitor with APC's D5 protein modification, the tumors were eradicated. As well, subsequent experiments showed that the animals were immune to rechallenge by the same tumor. APC plans to rapidly capitalize on these findings by expanding testing of its protein modifications to diverse treatment tumor models (that is breast, colon, lung). The company is currently in negotiations with contract research organizations (CROs) to pursue such additional testing over the next few months, and expects to conclude an agreement shortly. The context for these experiments is an unprecedented and development in cancer drug research, the robust single agent activity that has been observed with immune checkpoint inhibitors, which are regarded as the next big wave of cancer therapies. In contrast to traditional therapy, by mobilizing a patient's immune system, immunotherapies have been durable, rendering many patients cancer-free for years, and have persisted without off-target toxicity. Unfortunately, the majority of patients do not respond or will have an incomplete response to such checkpoint inhibitors by themselves. It is now established that such immune modulating antibody-based immunotherapies offer more benefit to the patient by being administered in combination with other forms of cancer management or in tandem with other immune modulating molecules. This approach is a basis for APC's current focus and has engendered a massive effort on the part of the pharmaceutical industry to discover such clinically viable drug combinations and bring them to market.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APC:CN C$0.23 CAD +0.015

APC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for APC.
View Industry Companies
 

Industry Analysis

APC

Industry Average

Valuation APC Industry Range
Price/Earnings 79.6x
Price/Sales -- Not Meaningful
Price/Book 17.4x
Price/Cash Flow 75.7x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVANCED PROTEOME THERAPEUTI, please visit www.advancedproteome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.